Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #5829944

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
USD
11,841,000 USD
USD
USD
11,841,000 USD
USD
10,548,000 USD
USD
10,548,000 USD
USD
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
9,887,000 USD
9,069,000 USD
Adjustments for decrease (increase) in inventories
503,000 USD
14,434,000 USD
Adjustments for share-based payments
11,248,000 USD
9,251,000 USD
Adjustments for fair value losses (gains)
4,990,000 USD
930,000 USD
Adjustments for undistributed profits of associates
1,758,000 USD
289,000 USD
Other adjustments for non-cash items
USD
1,079,000 USD
Interest received, classified as operating activities
5,201,000 USD
2,883,000 USD
Income taxes paid (refund), classified as operating activities
15,584,000 USD
655,000 USD
Cash flows from (used in) operating activities
1,795,000 USD
17,302,000 USD
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
790,000 USD
1,437,000 USD
Proceeds from sales of intangible assets, classified as investing activities
USD
21,279,000 USD
Purchase of intangible assets, classified as investing activities
6,000 USD
27,000 USD
Proceeds from sales of other long-term assets, classified as investing activities
2,098,000 USD
USD
Cash flows from (used in) investing activities
31,618,000 USD
129,388,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing other equity instruments
5,579,000 USD
8,133,000 USD
Payments of lease liabilities, classified as financing activities
4,008,000 USD
4,038,000 USD
Cash flows from (used in) financing activities
34,412,000 USD
1,039,000 USD
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
4,589,000 USD
147,729,000 USD
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
2,208,000 USD
2,128,000 USD
Cash and cash equivalents
54,944,000 USD
61,741,000 USD
207,342,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.